SEC Form 3 · accession 0001193125-26-330979
Obsidian Therapeutics, Inc. · OBX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Norkunas
Director
Period of report
Aug 3, 2026
Accepted (ET)
Aug 3, 2026 · 6:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0002130606
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 30,937 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.78 | holding | — | — | — | — | May 24, 2033 | Common Stock | 180,000 | — | D |
| Stock Option (Right to Buy)F2 | $0.78 | holding | — | — | — | — | Jun 24, 2034 | Common Stock | 51,563 | — | D |
Explanation of responses
- F1The shares underlying this option vest in sixteen (16) equal quarterly installments following June 30, 2023, subject to the Reporting Person's continued service on each such vesting date.
- F2The shares underlying this option vest in sixteen (16) equal quarterly installments following June 25, 2024, subject to the Reporting Person's continued service on each such vesting date.
Remarks
Exhibit 24 - Power of Attorney